

ADVANCES IN TRANSLATIONAL RESEARCH

Instructions for Authors (updated 24 November 2025)

AIMS AND SCOPE

ADVANCES IN TRANSLATIONAL RESEARCH provides a unique platform for cutting-edge research at the intersection of pharmacology, applied bioinformatics, and translational sciences. It aims to expand the horizons of translational pharmacology by bridging the gap between fundamental scientific discoveries and their practical applications, with a strong emphasis on big data analytics and computational methodologies in biomedical research. The journal welcomes papers contributing to a deeper understanding of drug discovery, pharmacological mechanisms, biomarker research and validation, utilization of large datasets and artificial intelligence, new methodological innovations across the entire translational research pipeline, and the therapeutic implications of the above.

EDITORIAL BOARD INFORMATION

ADVANCES IN TRANSLATIONAL RESEARCH is handled by an independent Editorial Board of autonomous scholars. Free from any external influence, they decide about the journal's policies in general. The names and affiliations of the Editorial Board members can be found on the journal's web page.

ADDRESS OF THE EDITORIAL OFFICE

Editors-in-Chief: Balázs Gyórfy, Zoltán Ungvári
Email: editor-in-chief@atrjournal.com

PUBLICATION SCHEDULE

One volume of two issues is published every year.

DIGITAL ARCHIVE

The entire journal content is archived in the [Portico](#) preservation archive.

SUBMISSION INFORMATION

ADVANCES IN TRANSLATIONAL RESEARCH strives to publish high quality and original papers, which adhere to the scope of journal. Papers are accepted on the basis of scientific significance and suitability for publication. Submission to the journal implies that the work is original, unpublished, not under consideration elsewhere, and will not be republished in any form or language without the consent of the editor and publisher.

Every submission is scanned against plagiarism using the program iThenticate. The instructions for ADVANCES IN TRANSLATIONAL RESEARCH submissions are in accord with the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" of the International Committee of Medical Journal Editors (<http://www.icmje.org>). Not fulfilling these criteria may lead to desk rejection of a submitted manuscript. Editorial board members may submit manuscripts, but the handling editor must be independent of the authors. Their role at the journal must be disclosed in the Conflict of Interest statement. To prevent malpractice, editors in the OJS system can only access articles assigned to them.

SUBMISSION PORTAL

Authors should submit their manuscripts using the OJS online manuscript submission and peer review system at <https://submit.akademiai.com/atr/index.php/atr/about/submissions>.

ADVANCES IN TRANSLATIONAL RESEARCH

Instructions for Authors (updated 24 November 2025)

REVIEW PROCESS

Each paper will be evaluated, whenever possible, by two independent and unbiased peer reviewers, chosen avoiding any conflict of interest. A single-blind review process is used, in which the reviewers' identities are hidden to the authors while the reviewers are aware of the authors' identity. Unpublished results are treated strictly confidentially. Papers accepted for publication are subject to editorial revision.

COPYRIGHT AND LICENCE POLICY

ADVANCES IN TRANSLATIONAL RESEARCH is a Gold Open Access journal.

By default, the articles are published under the *Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licenses* [Copyright Terms](#). With that, the authors grant to Akadémiai Kiadó Zrt. (hereafter the Publisher) an irrevocable nonexclusive license to publish the article in electronic and print format, and further sublicense the article in its original language throughout the world. The Publisher has the exclusive right to publish the article first.

The Authors shall declare and warrant that

- they are the exclusive author of the article along with the above indicated co-authors and have the approval of all the other co-authors to publish the article in its current form,
- the article is their own intellectual product,
- the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third-party rights,
- there is no plagiarism in the article, the content is punctual and true to the best of the Author's knowledge, it does not include any libel, or parts that are obscene or violate the copyrights, private life or any other rights of a third party, or that are illegal and shall warrant that the manuscript is not partly or entirely under review or being published at any other journals either in English or in any other languages,
- Authors shall accept that they shall provide the exact location of the first publication of the article when making the article available to any third party and shall enclose the link to the location of the first publication in the following format: (<https://doi.org/> [The DOI-number of the article without brackets]).

The Publisher shall be entitled to the following – not exclusive - rights of use after the first publication:

- To make the article available to the public for download on their own official publisher webpage without any time restriction.
- To utilize the article for commercial purposes individually or for the entire journal without any geographic or time limitation (for subscribers, one-off downloaders, one-off buyers of the article archive, etc.).
- To convert the article into the optional electronic format, to copy the article on a PC or electronic data medium.
- To publish the article in the electronic and printed journals indicated on the official publisher homepage, also including those journals that are partially or entirely available to a third party against a subscription fee.
- To share the publishing and rights of use with any other third party, respectively exercise these rights together with a third party.

ADVANCES IN TRANSLATIONAL RESEARCH

Instructions for Authors (updated 24 November 2025)

- To translate the article into a different language.
- To represent the author in the case of conducts of infringement of rights, unauthorized usage or violation of copyrights.
- To exercise all those rights that any third party is entitled to according to the license terms “CC BY NC ND” indicated above.

Authors can also opt for [CC-BY](#) license.

Above license information is also available through Sherpa Romeo.

For more information on Akadémiai Kiadó’s Open Access policy visit our [website](#).

AUTHOR CHARGES

There are no author fees of any kind: no processing, page, or colour illustration charges.

ETHICAL STATEMENT

ADVANCES IN TRANSLATIONAL RESEARCH and Akadémiai Kiadó are committed to the protection of animal and human research subjects and ethical practices in science publishing and therefore studies submitted to the journal must have been conducted in accordance with all applicable local and international standards. Akadémiai Kiadó follows the guidelines of the Committee on Publication Ethics (COPE)’s [Principles of Transparency and Best Practice in Scholarly Publishing](#), and [best practices](#). All authors are expected to be aware and follow the [Ethical Guide of Akadémiai Kiadó](#), conform to the highest standards of ethical conduct in the submission of accurate data, acknowledging the work of others, and divulging potential conflicts of interests. Studies submitted to ADVANCES IN TRANSLATIONAL RESEARCH must have been conducted in accordance with the [Declaration of Helsinki](#) and according to requirements of all applicable local and international standards.

AUTHORSHIP

All persons designated as authors should qualify for authorship based on the ICMJE criteria:

- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- Drafting the work or reviewing it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

By submitting a manuscript, the corresponding author affirms that they had access to all data from the study, both what is reported and what is unreported, and also that they had complete freedom to direct the analysis and its reporting, without influence from any sponsors. Manuscript drafts by sponsor employees not listed as authors are prohibited.

Changes in authorship and in authors’ order are not allowed after the submission of a manuscript, only in exceptional, well-grounded cases, supported with a declaration signed by all interested authors. The Editors-in-Chief must approve any change in authorship.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All authors must disclose financial relationships at submission and provisional acceptance, and update them until publication. Disclosures include study funding (governmental, non-profit, or commercial), non-financial support

ADVANCES IN TRANSLATIONAL RESEARCH

Instructions for Authors (updated 24 November 2025)

(e.g. drugs, analytic help), and individual financial ties within the past 36 months, such as equity, royalties, patents, or grants. Income from pharmaceutical companies must specify its purpose. Statements are reviewed for potential bias, and manuscripts may be rejected if concerns arise. Authors should contact the editor at any stage if uncertain about required disclosures.

PREPARATION OF THE MANUSCRIPTS

Manuscripts should be written in clear, concise, and grammatically correct English. Pages should be numbered consecutively, the title page being page one. An electronic version of the manuscript should be submitted in MS Word files, along with a complete PDF version (with figures, tables, appendices, and supplementary materials, if any) for the review process. The authors are responsible to obtain and provide written permission for reprinting previously published illustrations or tables.

Authors are encouraged follow PRISMA guidelines for systematic reviews and meta-analyses, CONSORT for clinical trials, CARE guidelines for case reports, STARD Checklist for reporting diagnostic accuracy, and STROBE Checklist for observational studies (cohort, case-control, or cross-sectional studies).

ETHICS SECTION

Studies submitted to the [ADVANCES IN TRANSLATIONAL RESEARCH](#) must have been conducted in accordance with the Declaration of Helsinki and according to requirements of all applicable local and international standards. Whenever it applies, in manuscripts reporting clinical investigations the authors should include the relevant ethical statements in the Methods section, e.g., that the study procedures were carried out in accordance with the Declaration of Helsinki, the Institutional Review Board of the ... approved the study, all subjects provided informed consent, or the consent has been waived by the local or national ethics committee.

PUBLICATION OF ACCEPTED MANUSCRIPTS

At the authors' request, the journal posts accepted manuscripts online immediately as plain PDFs, with supplementary material, until replaced by the final version. Both versions share the same DOI. During revision, authors must upload two identical-content files: one with tracked changes for review, and one clean, publication-ready file (including figures and tables) to serve as the accepted manuscript.

TYPES OF MANUSCRIPTS

Original Research Papers reporting high quality original results of research (examples: pharmacogenomic study, pre-clinical study, bioinformatic tool, drug mechanism study, meta-analysis, intervention study, cohort study).

Structure of the main body of text:

- Manuscript title
- Full author names, affiliations, ORCID IDs and contact details of the corresponding author
- Structured abstract (Background and Aim, Methods, Results, Conclusions) and keywords on a separate page in maximal 350 words
- Manuscript text (maximal 5000 words)
- Maximal 5 figures/tables, inserted in their intended places
- References (maximal 60)

Review Articles for a topic that has a general interest to the community.

Structure of the main body of text:

- Manuscript title
- Full author names, affiliations, ORCID IDs and contact details of the corresponding author
- Unstructured abstract (max 350 words) and keywords as a separate page

ADVANCES IN TRANSLATIONAL RESEARCH

Instructions for Authors (updated 24 November 2025)

- Format for manuscript text may vary (maximal 8000 words)
- Maximal 8 figures/tables, inserted in their intended places
- References (maximal 200)

Commentaries express points of view on scientific matters or published papers. Typically, Commentaries are solicited by the editors. A Commentary typically should not exceed 2000 words.

Letters to the Editors Brief letters (maximum of 1000 words, including references) will be considered for publication. Letters should not include figures and tables.

COVER LETTER

Submitting a cover letter is optional.

ORCID POLICY

All authors are requested to provide their ORCID ID when submitting their manuscript. For more information about ORCID, please visit (<https://orcid.org/>).

KEYWORDS

Keywords (maximum 10) should be added for each manuscript, immediately after the abstract. The keywords should include the focus areas of the journal (e.g. pharmacology, pharmacotherapy, pharmacogenomics, drug discovery, pharmacological mechanisms, biomarker research, biomarker validation, applied bioinformatics, translational sciences, big data analytics, artificial intelligence).

MANUSCRIPT TEXT

The text of the manuscript should be divided into sections with the headings: Introduction, Methods, Results, Discussion, References (in original papers). All abbreviations should be spelled out when first used in the text. Quantities should be expressed in SI units.

STATEMENTS

At the end of the manuscript, before the References section, please add the following statements:

Authors' contribution. Specify each author's contribution using the monograms of the authors and specify their roles in preparing the manuscript. State that all authors reviewed the final version of the manuscript.

Funding sources. State even if no funding was obtained by writing: "No financial support was received for this study."

Conflict of interests. All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationship with other individuals or organizations within 36 months of beginning the work submitted that could inappropriately influence, or be perceived to influence, their work. If none, state: "The authors have no conflict of interest to disclose."

Ethical aspects. All studies must have a short description on the ethics regarding the study either in the Methods section or at the tail of the article. State even if no approval was necessary.

Data availability. Authors must state data availability. If unavailable, justify legal, ethical, or other constraints.

AI use statement when necessary.

ADVANCES IN TRANSLATIONAL RESEARCH

Instructions for Authors (updated 24 November 2025)

REFERENCES

The journal uses numbered Vancouver referencing style, please prepare the paper accordingly.

TABLES AND FIGURES

Tables must be self-explanatory, numbered consecutively with Arabic numerals, and cited in the text. Each table should appear in their intended placement, with a number and title above and explanatory notes (including abbreviations) below. Figures must be high quality (≥ 300 DPI for images, ≥ 1200 DPI for line art, ≥ 600 DPI for mixed). Number figures consecutively with Arabic numerals, cite them in the text, and provide legends in their intended placement. When necessary, submit the figures as separate TIF or JPG files named by figure number.

CENTRAL ILLUSTRATION

Authors are encouraged to include a Central Illustration summarizing the main message of the paper. A key figure from the manuscript suitable for social media may be used.

PROOF

Proof corrections have to be made on our online platform (called *Proof Central*). A link to the copyedited proof will be sent to the author within two weeks via e-mail. Authors should review the proof and return the requested corrections within 72 hours. Please note that authors are urged to check their proofs carefully before submitting corrections since late corrections cannot be guaranteed for inclusion and post-publication corrections are only possible in an erratum. Corrections to the proofs must be restricted to existing errors. Rewriting the text or modifying authorship is not accepted in the proof stage, the publisher's Correction Policy is available [here](#). The final version of the article cannot be published until the authors return the proofs. Once corrections are returned and queries are addressed and resolved, the final version of the article will be posted on the journal site

CORRECTION POLICY

The publisher's Correction Policy is available [here](#).

ARTIFICIAL INTELLIGENCE (AI) USE

The publisher's policy on Artificial Intelligence (AI) use is available [here](#).